Product Images Aripiprazole

This is a list detailing the effects of different drugs on the pharmacokinetics of aripiprazole. It includes details such as cytochrome P450 enzyme inhibitors and inducers, gastric acid blockers, and specific drug interactions. The figure provides information on fold changes and confidence intervals related to aripiprazole when interacting with various drugs. This data can be helpful in understanding how these medications may impact the metabolism and effectiveness of aripiprazole.*

This text discusses the effects of intrinsic factors on the pharmacokinetics of aripiprazole, including special populations like poor vs. extensive metabolizers, gender differences, age groups, and hepatic impairment categories. It also touches on the impact of renal impairment. The data presented in figure 4 shows the fold change and 90% confidence interval for various comparisons.*

This is a table showing the effects of intrinsic factors on the pharmacokinetics of dehydro-aripiprazole. It includes comparisons based on CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, ALT levels, and renal impairment levels. The table shows fold changes and confidence intervals for AUC and Cmax based on different intrinsic factors.*

This document presents a figure showing the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a schizophrenia study comparing aripiprazole with placebo. The chart displays the number of subjects at risk for each treatment group over time in days from randomization. This information is valuable for understanding the relapse rates of patients in the study.*

This study (Bipolar Study 7) compares the relapse rates of patients taking Aripiprazole versus Placebo. The Kaplan-Meier estimation plot shows the cumulative proportion of patients experiencing relapse over time. The number of subjects at risk for each treatment group is shown at various time points. The study tracked patients from the time of randomization to monitor relapse rates.*

This is a graph showing the Kaplan-Meier estimation of the cumulative proportion of patients experiencing a relapse to any mood event in a Bipolar Study 8. The X-axis represents the days from randomization while the Y-axis displays the proportion with relapse.*

This description includes information about a package labeled as "Abilify 10mg Tablet" manufactured by Torrent Pharmaceuticals Limited. The package contains 30 tablets with an expiration date of MM/YY. It also provides the NDC number as 6362970031. The package should be stored at room temperature between 20°C-25°C (68°F-77°F) and emphasizes keeping all drugs out of reach of children.*